Anne Pesenson, MD
Nephrology · Seattle, WANPI 1083765515
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,850 of the $9,557 with a category attached, or 82.1%. Travere Therapeutics, Inc. accounts for 97.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $6,846 and has fallen 98.7% since, to $92 in 2025. Among nephrology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $455.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$9K
- Gilead$137
- Amgen$92
What the payments were for
- Consulting fees$7,85082%
- Travel & lodging$94210%
- Food & beverage$7638%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 18 | $9,328 |
| Gilead | 1 | $137 |
| Amgen | 2 | $92 |
How this compares
$9,557 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 33 | $40,695 |
| JardianceEmpagliflozin | 16 | $20,021 |
| Sevelamer Carbonate | 49 | $13,460 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $5,381 |
| Potassium Citrate ErPotassium Citrate | 31 | $4,204 |
| Calcitriol | 202 | $3,068 |
| Cinacalcet Hcl | 32 | $2,595 |
| Lisinopril | 170 | $1,470 |
| Bumetanide | 34 | $1,379 |
| Metoprolol Succinate | 69 | $1,316 |
| Calcium Acetate | 14 | $1,286 |
| Amlodipine Besylate | 154 | $1,223 |
| Tamsulosin Hcl | 60 | $1,170 |
| Chlorthalidone | 42 | $1,094 |
| Furosemide | 153 | $1,088 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Seattle
- Osama AmroSeattle$395K
- Ian de BoerSeattle$117K
- Nicolae LecaSeattle$101K
- Syeda AhmadSeattle$68K
- Stuart ShanklandSeattle$10K
- Lisa NakamotoSeattle$9K
- Nisha BansalSeattle$8K
- Michael TekesteSeattle$6K
- Sarah SanghaviSeattle$4K
- Bryan KestenbaumSeattle$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.